BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, December 18, 2025
Home » Blogs » BioWorld MedTech Perspectives » Is open source the future of pharma and med tech, or an anomaly?

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech

Is open source the future of pharma and med tech, or an anomaly?

Sep. 18, 2017
By Katie Pfaff

smart doctor hand working with modern laptop computer in modern office with virtual icon diagramTechnology seems to leap ahead at an astounding pace and is disruptive for many businesses, but is achingly slow for patients who await disease detection and treatments. A recent TED Radio Hour, “Fighting Cancer,” included speakers who addressed their approaches to speeding the move toward more precise and faster-acting cancer diagnostics and targeted therapies. James Bradner of Dana Farber Cancer Institute, and president of Novartis Institutes for Biomedical Research, was part of a research team which shared the molecule they discovered to treat a rare form of cancer publicly. The normal steps after research of protecting the information and developing proprietary therapies based on that data, was shirked to share the chemical formula for the molecule and to open it to research teams worldwide. At the time of the TED talk, about 40 labs had taken up the offer and were working with the molecule. There are numerous examples of groups which have opened up their research findings, or which seek to collaborate on projects. Open Source Imaging is an initiative seeking to build MR scanners mainly or completely comprised of “open source components.” The group plans to reduce costs and increase access to imaging technology, particularly in areas across the globe where access is limited. Is this an anomaly in the med-tech field, or a trend that is gaining traction? It will be interesting to see if more open source groups crop up, and how those open source firms fare in the  med-tech research space.

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 17, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 17, 2025.
  • Novo Nordisk semaglutide pill

    CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

    BioWorld
    A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
  • EU flag vector

    European Commission floats multiple fixes for MDR, IVDR

    BioWorld MedTech
    The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European Commission floated a series of...
  • Acute myeloid leukemia illustration

    Apollo’s APL-4098 shows potent antileukemic effects

    BioWorld Science
    Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing